Clinical Trials Resource Center

Soft Tissue Infections Clinical Trials

A listing of Soft Tissue Infections medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Arizona

Phoenix Arizona 85008

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Tucson Arizona 24857

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

California

Loma Linda California 92354

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Los Angeles California 90502

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Los Angeles California 90033

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Orange California 92868

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Sacramento California 95817

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

San Diego California 92123

A clinical trial to evaluate treatments using Tedizolid Phophate 200 mg, IV to oral for 6 days and Antibiotic comparator for patients with Skin Diseases, Infectious or Skin Diseases, Bacterial Skin Diseases (cSSTI)

San Diego California 92103

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Colorado

Denver Colorado 80204

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Denver Colorado 80045

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Connecticut

New Haven Connecticut 06520

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

District of Columbia

Washington District of Columbia 20010

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Florida

Gainesville Florida 32610

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Miami Florida 33136

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Iowa

Iowa City Iowa 52242

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Kentucky

University of Kentucky Chandler Medical Center
Lexington Kentucky 40536

Research Study for Patients with Radiation Necrosis

Lexington Kentucky 40536

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Louisiana

New Orleans Louisiana 70112

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Maine

Portland Maine 04102

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Maryland

Baltimore Maryland 21201

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Massachusetts

Boston Massachusetts 02115

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Boston Massachusetts 02114

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Michigan

Ann Arbor Michigan 48109

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Detroit Michigan 48202

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Detroit Michigan 48201

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Detroit Michigan 48235

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Royal Oak Michigan 48073

A clinical trial to evaluate treatments using Tedizolid Phophate 200 mg, IV to oral for 6 days and Antibiotic comparator for patients with Skin Diseases, Infectious or Skin Diseases, Bacterial Skin Diseases (cSSTI)

Minnesota

Minneapolis Minnesota 55455

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Missouri

Columbia Missouri 65211

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Kansas City Missouri 64108

A clinical trial to evaluate treatments using Tedizolid Phophate 200 mg, IV to oral for 6 days and Antibiotic comparator for patients with Skin Diseases, Infectious or Skin Diseases, Bacterial Skin Diseases (cSSTI)

New Jersey

Camden New Jersey 08103

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

New Mexico

Albuquerque New Mexico 87106

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

New York

Bronx New York 10461

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Bronx New York 10467

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Buffalo New York 14215

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Staten Island New York 10305

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

North Carolina

Charlotte North Carolina 28208

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Greenville North Carolina 27834

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Ohio

Cincinnati Ohio 45219

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Cleveland Ohio 44109

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Columbus Ohio 43210

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Dayton Ohio 45409

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Toledo Ohio 43606

A clinical trial to evaluate treatments using Tedizolid Phophate 200 mg, IV to oral for 6 days and Antibiotic comparator for patients with Skin Diseases, Infectious or Skin Diseases, Bacterial Skin Diseases (cSSTI)

Youngstown Ohio 44501

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Oregon

Portland Oregon 97239

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Pennsylvania

Bethlehem Pennsylvania 18015

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Philadelphia Pennsylvania 19104

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Pittsburgh Pennsylvania 15213

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene